TROG Cancer Research
Members Login   CQMS Login

Lung trials now recruiting patients

Our lung cancer trials are focused on the benefits and side effects of radiotherapy.

TROG 17.02 (OUTRUN) - The aim of this study is to compare the effects of Osimertinib alone versus Osimertinib plus Stereotactic Radiosurgery (SRS) on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors.

Primary sponsor: TROG


TROG 16.03 (CORE) - This study aims to show that the addition of SBRT (stereotactic body radiotherapy) to standard of care improves progression-free survival for patients with extra-cranial oligometastatic disease that has spread from their lung, breast and/or prostate cancer.

Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG


TROG 16.01 (NIVORAD) - A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

Primary sponsor: The University of Sydney
Collaborating groups: ALTG and TROG

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.